Halozyme Therapeutics Inc (NASDAQ:HALO) currently has a daily average trading volume of 2.20M but it saw 1367673 shares traded in last market. With a market cap of 6.64B USD, the company’s current market price of $53.85 came rising about 1.01 while comparing to the previous closing price of $53.31. In past 52 weeks, the stock remained buoying in the range of price level as high as $70.50 and as low as $42.01.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Morgan Stanley which downgraded the stock as “Equal-Weight” in its note to investors issued on May 14, 2025, recommending a price target of $62 for it. Leerink Partners downgraded its recommendation for the stock as a “Underperform” from “Market Perform” on May 13, 2025 while assigning a price target of $47. Wells Fargo also issued its recommendations for the stock as it downgraded the price target for the stock in the range of between $58 and $62.
Over the week, HALO’s stock price is moving -1.07% down while it is -11.17% when we observe its performance for the past one month. Year-to-date it is 12.63% up and over the past year, the stock is showing an upside performance of 21.58%.
The company is expected to be releasing its next quarterly report in July, for which analysts forecasted an EPS of 1.2 while estimate for next year EPS is 5.32. In next quarter, company is expected to be making quarterly sales of $331.47M as analysts are expecting the sales for current fiscal year at $1.25B and seeing the company making $1.48B in sales next year. Moreover, analysts are in estimates of $282.66M for current-quarter revenue.
Currently, Halozyme Therapeutics Inc’s total number of outstanding shares is 123.17M with 1.17% of that held by the insiders while 102.13% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 24.39% and return on equity (ROE) at 147.06%. It has a price to earnings ratio (P/E ratio) of 14.29 while having a 7.52 of forward P/E ratio. Stock’s beta reads 1.19. Stock has a price to book (P/B) ratio of 13.75 while price to sale or P/S ratio amounts to 6.12. Its return on asset (ROA) is 24.04% on average.
